Thalia Therapeutics

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Media

AIM Rule 26

Regulatory news

Home

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

CEO Nigel Theobald and Non-Executive Director Alastair Smith recently hosted a detailed presentation and investor Q&A, providing key insights into N4 Pharma’s progress and future plans.

Updates on lead drug delivery platforms – including Nuvec® and LipTide™ and their potential applications.

Strategic roadmap & upcoming milestones – including pre-clinical developments and licensing opportunities.

Investor Q&A – addressing shareholder queries on commercial strategy, partnerships, and market positioning.

This was a valuable opportunity to gain deeper insight into the company’s direction. If you missed it or want to revisit any details, the full recording is now available.

Watch now and submit any additional questions below.

Corporate Presentation & Shareholder Q&A – Now Available